Erratum: Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome (Future Cardiology (2014) 10:6 (693-698))

Satnam Singh, Roger Beadle, Donnie Cameron, Amelia Rudd, Margaret Bruce, Baljit Jagpal, Konstantin Schwarz, Gemma Brindley, Fergus Mckiddie, Chim Lang, Dana Dawson, Michael Frenneaux

    Research output: Contribution to journalComment/debatepeer-review

    23 Downloads (Pure)

    Abstract

    Following publication of the Clinical Trial Protocol by Satnam Singh, Roger Beadle, Donnie Cameron, Amelia Rudd, Maggie Bruce, Baljit Jagpal, Konstantin Schwarz, Gemma Brindley, Fergus McKiddie, Chim Lang, Dana Dawson and Michael Frenneaux, titled ‘Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome’, which appeared in the December 2014 issue of Future Cardiology (Future Oncol. 10[6], 693–698 [2014]), it has been brought to our attention that the author names were presented incorrectly as:
    Satnam Singh, Roger Beadle, Donnie Cameron, Amelia Rudd, Maggie Bruce, Baljit Jagpal, Konstantin Schwarz, Gemma Brindley, Fergus Mckiddie, Peter Nightingale, Chim Lang, Dana Dawson and Michael Frenneaux.
    The correct presentation should be:
    Satnam Singh, Roger Beadle, Donnie Cameron, Amelia Rudd, Maggie Bruce, Baljit Jagpal, Konstantin Schwarz, Gemma Brindley, Fergus Mckiddie, Chim Lang, Dana Dawson and Michael Frenneaux.
    The authors and editors of Future Cardiology would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.
    Original languageEnglish
    Pages (from-to)245
    Number of pages1
    JournalFuture Cardiology
    Volume11
    Issue number2
    Early online date11 Mar 2015
    DOIs
    Publication statusPublished - Mar 2015

    ASJC Scopus subject areas

    • Molecular Medicine
    • Cardiology and Cardiovascular Medicine

    Fingerprint

    Dive into the research topics of 'Erratum: Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome (Future Cardiology (2014) 10:6 (693-698))'. Together they form a unique fingerprint.

    Cite this